Efficacy of Intravesical BCG in Patients with Bladder Cancer in the Tobruk City Population

Ahmed saeid Safieddine; Mabroka  Fathi layas; Amna  Abdel-Karim; Ghareeb Emraja; Rehab Mostafa

doi:10.54361/ljmr.v17i2.04

Authors

Ahmed saeid Safieddine Medical Laboratory Department, Faculty of Medical Technology, Tobruk Uni. Libya Author
Mabroka Fathi layas Tobruk Medical Center Author
Amna Abdel-Karim Tobruk Medical Center Author
Ghareeb Emraja Tobruk Medical Center urology department Author
Rehab Mostafa Tobruk Medical Center urology department . Author

DOI:

https://doi.org/10.54361/ljmr.v17i2.04

Keywords:

Bacterial therapy, BCG, TURBT, bladder cancer, NMIBC, , MIBC

Abstract

Background: The particular pathophysiology of tumors makes it difficult to treat cancer successfully, The survey's goal was to assess the predictive risk factors for bladder cancer and the efficiency of intravesical BCG as a local example of bacterial cancer therapy in reducing tumor recurrence rates The participants in this study were drawn from Tobruk City and the surrounding area, From January 2022 to June 2022, the study was conducted. Result: Overall, there were 47 patients in our statistical data had 47 patients with bladder cancer and was carried out in Tobruk City, Libya, from January 2022 to June 2022. Only 3.6% of the patients were female, with men making up the majority (93.6%). The study's participants' ages ranged from 2 to 87, with a mean of 59. 18 (38.2%) of the 47 individuals received care, compared to 29 (61.7%) who did not. 17 (94%) of the 18 patients who received BCG were men, and only one patient (0.5%) was a woman. 16 (34.0%) of the 47 patients had tumor recurrences, and 3 passed away. Four (25%) of the patients had conditions related to hypertension, diabetes, or the prostate, and 75% of them received BCG. The remaining 31 patients, with an average age of 50 and 6 (1.9%) undergoing BCG, were all in stable condition. Conclusion: The study found that BCG-immunotherapy effectively reduced NMIBC in 18 out of 47 patients in Tobruk City, with minimal side effects. However, specific risk factors reduced the effectiveness of BCG immunotherapy.

References

Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, and Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018; 68(6): 394-424. DOI: https://doi.org/10.3322/caac.21492

Felgner S, Pawar V, Kocijancic D, Erhardt M, Weiss S. Tumour-targeting bacteria-based cancer therapies for increased specificity and improved outcome. Microb Biotechnol. 2017; 10(5): 1074-1078. DOI: https://doi.org/10.1111/1751-7915.12787

Sun B, Luo C, Yu H, Zhang X, Chen Q, Yang W, et al. Disulfide Bond-Driven Oxidation- and Reduction-Responsive Prodrug Nanoassemblies for Cancer Therapy. Nano Lett. 2018; 18(6): 3643-3650. DOI: https://doi.org/10.1021/acs.nanolett.8b00737

Wijdeven RH, Pang B, Assaraf YG, Neefjes J. Old drugs, novel ways out: Drug resistance toward cytotoxic chemotherapeutics. Drug Resistance Updates. 2016;28: 65-81. DOI: https://doi.org/10.1016/j.drup.2016.07.001

Crawford S. Is it time for a new paradigm for systemic cancer treatment? Lessons from a century of cancer chemotherapy. Front Pharmacol. 2013;4 (18) JUN: 1-18 DOI: https://doi.org/10.3389/fphar.2013.00068

Zacharski LR, and Sukhatme VP. Coley’s toxin revisited: Immunotherapy or plasminogen activator therapy of cancer? Vol. 3, Journal of Thrombosis and Haemostasis. 2005; 3(3): 424-427. DOI: https://doi.org/10.1111/j.1538-7836.2005.01110.x

Richardson MA, Ramirez T, Russell NC, Moye LA. Coley toxins immunotherapy: A retrospective review. Altern Ther Health Med. 1999;5(3): 7-42.

Mangtani P, Abubakar I, Ariti C, Beynon R, Pimpin L, and Fine PEM, et al. Protection by BCG vaccine against tuberculosis: A systematic review of randomized controlled trials. Clinical Infectious Diseases. 2014;58(4): 80-470 DOI: https://doi.org/10.1093/cid/cit790

Redelman-Sidi G, Glickman MS, Bochner BH. The mechanism of action of BCG therapy for bladder cancer--a current perspective. Nat Rev Urol. 2014 Mar;11(3):153-62. DOI: https://doi.org/10.1038/nrurol.2014.15

Pettenati C, Ingersoll MA. Mechanisms of BCG immunotherapy and its outlook for bladder cancer. Nat Rev Urol. 2018 Oct; 15(10):615-625. DOI: https://doi.org/10.1038/s41585-018-0055-4

Shariat SF, Sfakianos JP, Droller MJ, Karakiewicz PI, Meryn S, Bochner BH. The effect of age and gender on bladder cancer: a critical review of the literature. BJU Int. 2010 Feb;105(3):300-8. DOI: https://doi.org/10.1111/j.1464-410X.2009.09076.x

Xu Y, Huo R, Chen X, Yu X. Diabetes mellitus and the risk of bladder cancer: A PRISMA-compliant meta-analysis of cohort studies. Medicine (Baltimore). 2017 Nov;96(46):e8588. DOI: https://doi.org/10.1097/MD.0000000000008588

Huang WL, Huang KH, Huang CY, Pu YS, Chang HC, Chow PM. Effect of diabetes mellitus and glycemic control on the prognosis of non-muscle invasive bladder cancer: a retrospective study. BMC Urol. 2020;20(1):117. DOI: https://doi.org/10.1186/s12894-020-00684-5

Lee J, Giovannucci E, Jeon JY. Diabetes and mortality in patients with prostate cancer: a meta-analysis. Springerplus. 2016 Sep 13;5(1):1548. DOI: https://doi.org/10.1186/s40064-016-3233-y

Hong S, Kim SC, Kwon T, Jeong IG, Kim CS, Ahn H, Hong JH. Is bladder tumor location associated with prostate cancer detection after intravesical bacillus Calmette-Guérin instillation? PLoS One. 2014 Jul 29;9(7):e103791. DOI: https://doi.org/10.1371/journal.pone.0103791

Teoh JY, Mackenzie G, Smith M, Yuen SK, Gudaru K, Leow JJ, Leung CH, Ng CF, Loeb S. Understanding the Composition of a Successful Tweet in Urology. Eur Urol Focus. 2020 May 15;6(3):450-457. DOI: https://doi.org/10.1016/j.euf.2019.08.008

Rink M, Xylinas E, Babjuk M, Hansen J, Pycha A, Comploj E, Lotan Y, Sun M, Karakiewicz PI, Abdennabi J, Fajkovic H, Loidl W, Chun FK, Fisch M, Scherr DS, Shariat SF. Impact of smoking on outcomes of patients with a history of recurrent nonmuscle invasive bladder cancer. J Urol. 2012 Dec;188(6):2120-7. DOI: https://doi.org/10.1016/j.juro.2012.08.029

Seretis A, Cividini S, Markozannes G, Tseretopoulou X, Lopez DS, Ntzani EE, Tsilidis KK. Association between blood pressure and risk of cancer development: a systematic review and meta-analysis of observational studies. Sci Rep. 2019 Jun 12;9(1):8565. DOI: https://doi.org/10.1038/s41598-019-45014-4

Yurdakul T, Avunduk MC, Piskin MM. Pure squamous cell carcinoma after intravesical BCG treatment. A case report. Urol Int. 2005;74(3):283-5. DOI: https://doi.org/10.1159/000083566

Oddens JR, Sylvester RJ, Brausi MA, Kirkels WJ, van de Beek C, van Andel G, de Reijke TM, Prescott S, Witjes JA, Oosterlinck W. The effect of age on the efficacy of maintenance bacillus Calmette-Guérin relative to maintenance epirubicin in patients with stage Ta T1 urothelial bladder cancer: results from EORTC genito-urinary group study 30911. Eur Urol. 2014 Oct;66(4):694-701. DOI: https://doi.org/10.1016/j.eururo.2014.05.033

Leow JJ, Bedke J, Chamie K, Collins JW, Daneshmand S, Grivas P, Heidenreich A, Messing EM, Royce TJ, Sankin AI, Schoenberg MP, Shipley WU, Villers A, Efstathiou JA, Bellmunt J, Stenzl A. SIU-ICUD consultation on bladder cancer: treatment of muscle-invasive bladder cancer. World J Urol. 2019 Jan;37(1):61-83. DOI: https://doi.org/10.1007/s00345-018-2606-y

Sanli O, Dobruch J, Knowles MA, Burger M, Alemozaffar M, Nielsen ME, Lotan Y. Bladder cancer. Nat Rev Dis Primers. 2017 Apr 13;3:17022. DOI: https://doi.org/10.1038/nrdp.2017.22